Joshua Pinto Sells 5,967 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) President Joshua Pinto sold 5,967 shares of Neumora Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $3.54, for a total value of $21,123.18. Following the completion of the transaction, the president owned 57,783 shares in the company, valued at $204,551.82. The trade was a 9.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Neumora Therapeutics Trading Down 3.1%

Shares of Neumora Therapeutics stock traded down $0.11 on Thursday, reaching $3.48. 1,491,798 shares of the company were exchanged, compared to its average volume of 2,331,130. Neumora Therapeutics, Inc. has a fifty-two week low of $0.61 and a fifty-two week high of $3.65. The firm has a market capitalization of $581.47 million, a price-to-earnings ratio of -2.37 and a beta of 3.20. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The stock has a fifty day moving average price of $2.15 and a 200-day moving average price of $2.05.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its position in Neumora Therapeutics by 23.8% in the 4th quarter. Invesco Ltd. now owns 227,594 shares of the company’s stock worth $407,000 after buying an additional 43,795 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Neumora Therapeutics in the fourth quarter worth $204,000. Ikarian Capital LLC increased its stake in shares of Neumora Therapeutics by 10,128.9% in the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock worth $2,288,000 after acquiring an additional 1,265,910 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its holdings in shares of Neumora Therapeutics by 74.8% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 72,106 shares of the company’s stock worth $129,000 after acquiring an additional 30,866 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Neumora Therapeutics by 80.1% during the fourth quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock valued at $6,474,000 after purchasing an additional 1,608,266 shares during the last quarter. Institutional investors and hedge funds own 47.65% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on NMRA. William Blair upgraded shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $4.00 to $7.00 in a research note on Monday, December 1st. Leerink Partners assumed coverage on shares of Neumora Therapeutics in a research report on Monday, January 12th. They set an “outperform” rating and a $8.00 price objective on the stock. Needham & Company LLC increased their target price on Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Finally, Mizuho set a $6.00 target price on Neumora Therapeutics in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.13.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.